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Abstract 
Oral immunomodulatory drugs (IMiDs), namely thalidomide, lenalidomide and pomalidomide, 
interfere with several pathways important for disease progression. Today they play a crucial role in 
the treatment of multiple myeloma patients, and have considerably improved myeloma outcomes. 
These agents, and thalidomide in particular, are associated with higher rates of thromboembolic 
events, both venous and arterial. Individual risk factors for thromboembolic events include 
advanced age, previous history of thromboembolism, an indwelling central venous catheter, 
comorbid conditions (e.g. infections, diabetes, cardiac disease, obesity), current or recent 
immobilization, recent surgery and inherited thrombophilic abnormalities. Cancer therapy and 
cancer itself also increase the risk of thromboembolic events. The aim of this review is to help 
clinicians to define the risk of thrombotic events in patients treated with thalidomide and thus to 
provide practical recommendations to manage thromboprophylaxis in these patients. 
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Introduction 
Thalidomide belongs to the category of immunomodulatory drugs (IMiDs) together with the 
second-generation lenalidomide and pomalidomide. IMiDs have been shown to block several 
pathways important for disease progression demonstrating anti-angiogenic, immunomodulatory and 
apoptotic effects [Anderson, 2005]. After being withdrawn from the world market because of its 
teratogenicity, thalidomide is today approved for the therapy of some inflammatory and 
autoimmune disorders, including certain late-stage AIDS symptoms, and plays a crucial role in the 
therapy of multiple myeloma. 
Trials have reported numerous thromboembolic events attributed to thalidomide therapy, especially 
when thalidomide is used in combination with chemotherapy. Deep vein thrombosis (DVT) and 
pulmonary embolism (PE) are more common, but occasional arterial thrombotic events have also 
been detected [Palumbo et al. 2008a; Scarpace et al. 2005]. 
Although the introduction of IMiDs and thalidomide in cancer therapy, and multiple myeloma in 
particular, has considerably improved outcome, they have also increased the risk of 
thromboembolic events. Accurate evaluation of thromboembolic risk and appropriate 
thromboprophylaxis are recommended to improve the safety profile of the thalidomide-based 
therapy and optimize patient outcome [Palumbo et al. 2008b]. 
Which antithrombotic agent is the most appropriate is still a matter of debate; aspirin (ASA), low-
molecular weight heparin (LMWH) and warfarin all seem to be effective. This review discusses risk 
factors for thromboembolism in the general population and, in particular, in multiple myeloma 
patients receiving thalidomide, and proposes clinical practical recommendations for 
thromboprophylaxis in this setting. 
Brief history of thalidomide 
Thalidomide is a synthetic glutamic acid derivative that consists of a chiral center and two amide 
rings. It is poorly soluble in water, hence no parental preparation is available (Figure 1). This drug 
exhibits linear and dose-dependent pharmacokinetics that are not affected by age, sex, race, food or 
smoking status [Weber, 2003]. 
 
Figure 1. Molecular structure of thalidomide and most common adverse events. DVT, deep vein 
thrombosis. 
Thalidomide and IMiDs inhibit the cytokines tumor necrosis factor-α (TNF-α), interleukins (IL) 1β, 
6, 12, and granulocyte macrophage-colony stimulating factor (GM-CSF). TNF-α enhances neo-
angiogenesis, and interacts with other proliferative cytokines such as IL-6, known to be involved in 
the pathogenesis of multiple myeloma [Thomas and Kantarjian, 2001]. Thalidomide also inhibits 
IL-12 monocyte production, and enhances lymphocytes synthesis of IL-12 determining an 
enhancement in the cytotoxic activity mediated by natural killer (NK) cells. IL1 β along with TNF-
α are implicated in tumorigenesis upregulating the expression of vascular cell adhesion molecules 
(VCAM) promoting cancer cell adhesion and metastasis [Vidal-Vanaclocha et al. 2000]. IMiDs 
induce an IL-2-mediated primary T-cell proliferation increasing NK cell numbers and function, thus 
increasing the activity of NK-dependent cytotoxicity. IMiDs cause a concomitant increase in 
interferon gamma (IFN-γ) production and decrease in the density of TNF-α-induced cell surface 
adhesion molecules ICAM-1, VCAM-1 and E-selectin, thus altering the interactions between 
myeloma cells and the bone marrow microenvironment. Finally, IMiDs activate apoptotic pathways 
through caspase-8-mediated cell death and, at the mitochondrial level, through the c-jun terminal 
kinase (JNK)-dependent release of cytochrome-c and Smac into the cytosol of cells [Anderson, 
2005]. 
Some of the above immunomodulatory activities along with anti-angiogenic, antiproliferative and 
pro-apoptotic properties are thought to mediate the antitumor responses to IMiDs observed in 
relapsed and refractory multiple myeloma and some solid tumor cancers [Teo, 2005]. 
Thalidomide was launched by Grünenthal on 1 October 1957; at first it was used as tranquilizer and 
painkiller and was effective against insomnia, coughs, colds and headaches. It was also found to be 
an effective antiemetic, with an inhibitory effect on morning sickness during pregnancy. In the early 
1960s the drug was withdrawn from the world market due to the discovery of its teratogenic effect 
(phocomelia). It has then been selectively reintroduced for use in various disorders thought to have 
an autoimmune or inflammatory basis. 
The drug has been used in a variety of dermatologic conditions during the past few decades, 
including erythema nodosum leprosum, prurigo nodularis, actinic prurigo, discoid lupus 
erythematosus, aphthous stomatitis, Behçet’s syndrome and graft-versus-host disease [Tseng et al. 
1996]. Researchers continue to investigate thalidomide for use in treating a variety of diseases and 
conditions, and nowadays it has become one of the most widely used drugs to treat multiple 
myeloma. Moreover, thalidomide has shown promising results for the treatment of inflammatory 
diseases, HIV-related mouth and throat ulcers and Kaposi’s sarcoma, but further investigation is 
needed. 
Thalidomide is a known teratogenic agent, and its use is absolutely contraindicated in pregnant 
women. Sedation, constipation and pruritus are its most frequently noted side effects. A 
sensorimotor peripheral neuropathy usually of hands and feet may occur, particularly after 
prolonged exposure. Less common effects include peripheral edema, tremors, bradycardia, 
hypothyroidism and rarely neutropenia and hepatic enzyme elevation [Weber, 2003]. Venous 
thromboembolism (VTE) events are commonly associated with the use of thalidomide [Scarpace et 
al. 2005]. Deep vein thrombosis (DVT) is the predominant event, occurring in veins deep within the 
muscles of the leg and in the pelvis; DVT occurs when part or all of a thrombus breaks away from 
the blood vessel wall; this clot or embolus is sometime carried in the direction of blood flow, to the 
pulmonary vessels. For this reason patients with DVT are at risk of PE as well, a life-threatening 
event. PE is a potentially lethal complication of DVT, leading to sudden death in one fourth of all 
cases [Heit et al. 1999]. 
Arterial thromboembolism is a sudden interruption of blood flow to an organ or body part due to a 
clot (embolus); it is increasingly being recognized as a complication of cancer therapy, although the 
underlying mechanisms are poorly understood [Lacy, 2010]. 
Atrial fibrillation (AF) is the most common arrhythmia seen in clinical practice; without appropriate 
anticoagulant treatment, most patients with AF are at increased risk of cardioembolic stroke. 
Coronary artery disease (CAD) is the most common form of cardiovascular disease. In CAD, 
atherosclerosis damages the coronary artery wall, predisposing to thrombus formation. The 
symptoms and severity of acute coronary syndromes (unstable angina and myocardial infarction) 
vary depending on the degree to which thrombi occlude the coronary arteries [Fuster et al. 2005; 
Bassand et al. 2007; Rosamond et al. 2008; Lloyd-Jones et al. 2010]. 
Thalidomide and multiple myeloma 
Thalidomide received the approval by the United States Food and Drug Administration (FDA) for 
use in combination with high-dose dexamethasone as treatment for newly diagnosed multiple 
myeloma in 2006. In 2008, the European Medicines Agency (EMEA) granted approval for 
thalidomide in the treatment of newly diagnosed multiple myeloma in combination with melphalan 
and prednisone. 
Thalidomide has been shown to have therapeutic activity as a single agent in patients with relapsed 
and/or refractory multiple myeloma. Thalidomide monotherapy can induce remissions in about one 
third of relapsing or refractory patients [Dimopoulos et al. 2003; Barlogie et al. 2001; Yakoub-Agha 
et al. 2002; Neben et al. 2002; Kumar et al. 2003] and combinations of thalidomide with 
dexamethasone and/or chemotherapy can further improve response rates in these patients 
[Dimopoulos et al. 2003; Kropff et al. 2003]. Studies have shown good efficacy of thalidomide 
treatment in untreated patients [Dimopoulos et al. 2003]. 
Thalidomide has a wide spectrum of biological effects, including some that have been hypothesized 
to promote thrombosis, such as transient reduction of soluble thrombomodulin levels during the 
first month of therapy [Corso et al. 2004] and restoration of endothelial cell PAR-1 expression after 
damage from cytotoxic agents such as doxorubicin [Kaushal et al. 2004]. The latter finding may in 
part explain the markedly higher thromboembolic risk seen with thalidomide–anthracycline 
combination therapy compared with thalidomide monotherapy, since IMiDs do not appear to cause 
endothelial injury themselves [Streetly et al. 2005]. Previous studies showed that single-agent 
thalidomide is not associated with an increased risk of thrombosis [Barlogie et al. 2001]. In 
relapsed/refractory multiple myeloma the incidence of VTE is <2% [Barlogie et al. 2001] and in 
newly diagnosed multiple myeloma the incidence of VTE is 3.5%. Combining thalidomide with 
dexamethasone has been clearly shown to increase the incidence of VTE; previous studies in newly 
diagnosed and relapsed/refractory multiple myeloma reported an incidence of 8–26% [Osman et al. 
2001; Corso et al. 2004]. A significant increase in the risk of VTE during treatment with 
thalidomide and anthracyclines has been reported, especially during the first months of therapy 
[Barlogie et al. 2006]. With regards to alkylating agents, a phase II trial involving 50 elderly 
patients receiving melphalan, thalidomide and dexamethasone as initial therapy the incidence of 
VTE was around 9% [Dimopoulos et al. 2006]. In a randomized control trial assessing response 
rates of elderly patients with newly diagnosed multiple myeloma to melphalan, prednisone and 
thalidomide (MPT) as compared with melphalan–prednisone (MP) therapy, the incidence of VTE 
was 17% in the MPT arm and 2% in the MP arm [Palumbo et al. 2006]. The highest incidence of 
VTE (58%) in myeloma therapy was reported in a phase II trial evaluating the use of doxorubicin, 
vincristine and dexamethasone with thalidomide both in newly diagnosed and in relapsed/refractory 
multiple myeloma patients [Baz et al. 2005]. 
Risk factors for thromboembolism in the general population 
Thromboembolism is typical of older age, with an incidence of less than 2% in subjects younger 
than 55 years and more than 5% in patients older than 65 years [Silverstein et al. 1998]. 
The cause of thromboembolism is multifactorial and is often a consequence of a combination of risk 
factors. Thromboembolic risk factors can be categorized into individual and disease-related risk 
factors [Samama, 2000; Heit et al. 2000, 2002; Ageno et al. 2006; Bauer, 2001]. 
Individual risk factors include older age, comorbid conditions (such as obesity, infection, renal 
disease, pulmonary disease and arterial thromboembolism), heritable prothrombotic mutations, the 
presence of a central venous catheter (CVC) or pacemaker, previous history of thrombosis, 
pregnancy/puerperium and use of drugs. 
Inherited thrombophilic abnormalities may include antithrombin III deficiencies, protein C and S 
deficiencies, activated protein C resistance, factor V Leiden mutation, prothrombin gene mutation 
and high levels of homocystein. 
Disease-related factors include recent (generally less than 3 months) surgical procedures, including 
vertebroplasty and kyphoplasty, trauma or hospital admission, neurologic disease with subsequent 
high degree and prolonged immobilization, chronic clinical conditions (hyperviscosity, chronic 
renal disease, infections, cardiac disease and malignant neoplasm, such as myeloma, with or 
without chemotherapy), primary site of cancer (gastrointestinal, brain, lung, gynecologic, renal or 
hematologic), initial 3–6 months after cancer diagnosis, antiangiogenic therapy (thalidomide, 
lenalidomide or bevacizumab) and erythropoiesis-stimulating agents 
The simultaneous presence of more than one risk factor increases the risk of VTE (Table 1). 
 
Table 1. Major risk factors for venous thromboembolism (VTE) and suggested actions. 
 
Risk of thromboembolism in patients with cancer 
The risk of thromboembolism is 7–10 times higher in patients with cancer compared with the 
normal population. The risk is considerably higher (28 times) in patients with hematologic cancer 
[Blom et al. 2005]. The pathophysiology of thrombosis in cancer is a complex process. The 
interaction between malignant cells and monocyte/macrophage cells stimulates the release of TNF, 
IL-1 and IL-6, all causing endothelial damage. The interaction between tumor cells and 
macrophages also activates platelets, factor XII and X. Cysteine protease and tissue factor are 
highly expressed in cancer cells, have procoagulant activity and can directly activate factor X and 
VII [Bick, 2003; Prandoni et al. 2005]. The risk is usually higher in the first months after diagnosis. 
In cancer patients, the risk of thromboembolic events is increased with active therapy, 
immobilization, surgery and the presence of CVC. In cancer patients undergoing surgery, the risk of 
DVT is doubled after surgery, and the risk of PE is three times as high as compared with patients 
without cancer undergoing surgery [White et al. 2003]. 
Recently, the risk of VTE was also found to be increased by the administration of erythropoiesis-
stimulating agents [FDA, 2010]. A previous trial reported an increased incidence of VTE in cancer 
patients treated with erythropoiesis-stimulating agents, doubled in patients using erythropoietin and 
treated with thalidomide compared with patients who were treated with thalidomide and not 
receiving erythropoietin [Anaisse et al. 2012]. To conclude, in cancer patients the risk of developing 
VTE is higher because of the presence of several risk factors, including cancer therapy itself. 
Thromboembolism in multiple myeloma patients treated with thalidomide 
Hypercoagulable states have been described in plasma cell dyscrasias without being specifically 
related to myeloma. The incidence of thromboembolic events in multiple myeloma varies from 3% 
to 10% [Srkalovic et al. 2004; Rajkumar et al. 2006]. Several mechanisms are implicated, yet the 
exact mechanisms associated with VTE in multiple myeloma are unclear. M-protein interacts with 
platelets, enhancing platelet adhesion and aggregation [Eby and Blinder, 2003]. Procoagulant 
antibody formation, paraprotein interference with fibrin structure, activated protein C resistance and 
endothelial damage may be considered important factors favoring thromboembolism in patients 
with multiple myeloma [Zangari et al. 2003]. The interaction between tumor cells and their 
microenvironment may explain the increased expression of von Willebrand and factor VIII. This 
close relationship may be responsible for increased secretion of proinflammatory cytokines such as 
IL-6 and TNF that can activate coagulation pathways [Fox and Kahn, 2005]. Thalidomide can 
enhance expression of tissue factor and vascular endothelial growth factor, downregulate 
thrombospondin and cause cytokine-mediated, activated protein C resistance. Thalidomide has been 
shown to increase the levels of von Willebrand factor and factor VIII. In addition thalidomide 
regulates the level of the prothrombotic factor COX-2 [Kristinsson, 2010]. 
In multiple myeloma, published studies showed that thalidomide alone as induction therapy or as 
maintenance approach after chemotherapy is associated with a low incidence of thromboembolism, 
below 5% [Rajkumar et al. 2003; Weber et al. 2003; Barlogie et al. 2001; Zonder, 2006] and that 
the major risk is in the first months after diagnosis. Thalidomide associated with dexamethasone 
was found to lead to increased thromboembolic risk. In a randomized trial by the Eastern 
Cooperative Oncology Group including 102 newly diagnosed patients with myeloma, the rate of 
thromboembolic events was 17% in subjects receiving thalidomide plus dexamethasone and 3% in 
those receiving dexamethasone alone [Rajkumar et al. 2006]. 
The VTE risk may decrease in relapsed/ refractory patients because they are more likely to be 
treated with lower doses of thalidomide [Zangari et al. 2007; Niesvizky and Badros, 2010]. 
There appears to be a striking increase in the risk of developing thromboembolic events during 
treatment with thalidomide–anthracycline combination regimens, particularly during the first 
months of therapy [Barlogie et al. 2006]. The risk of developing thromboembolism during therapy 
with thalidomide-alkylating agent combination therapy may be increased as well, but not to the 
same degree as with anthracyclines. The main chemotherapeutic regimens including thalidomide 
and the incidence of thromboembolic events are summarized in Table 2. 
 
Table 2. Incidences of thromboembolism with regimens including thalidomide plus alkylating agents. 
 
In conclusion, myeloma therapy-related risk factors include use of doxorubicin, high-dose steroids 
and combination chemotherapy [Bauer, 2001; Snowden et al. 2011]. 
Thromboprophylaxis approaches available 
Several classes of agents have been used for prophylaxis of VTE. Most commonly used 
pharmacologic agents for thromboprophylaxis of VTE include: ASA, unfractionated heparin (UH; 
standard, low-dose or adjusted-dose), oral anticoagulants such as warfarin and LMWH. 
To date, only one randomized study is currently available. This study compared the use of ASA and 
fixed low-dose warfarin versus LMWH to prevent thromboembolism in myeloma patients receiving 
thalidomide [Palumbo et al. 2011]; 667 patients with previously untreated myeloma who received 
thalidomide-containing regimens (with or without bortezomib), were randomly assigned to receive 
ASA (100 mg/day), warfarin (1.25 mg/day) or LMWH (enoxaparin 40 mg/day). There were 6.5% 
who had serious thromboembolic events, acute cardiovascular events or sudden death during the 
first 6 months (6.4% in the ASA group, 8.2% in the warfarin group and 5.0% in the LMWH group). 
Compared with LMWH, the absolute differences were 1.3% in the ASA group and 3.2% in the 
warfarin group. The risk of thromboembolism was 1.38 times higher in patients treated with 
thalidomide without bortezomib, suggesting a protective role of bortezomib against VTE. ASA and 
warfarin showed similar efficacy compared with LMWH, except in elderly patients, where warfarin 
was shown to be less effective than LMWH. 
LMWH 
The recommended dosage of LMWH in thalidomide treated patients is within the prophylactic 
range [Zangari et al. 2004]. The use of LMWH is more appropriate for cytopenic (mainly 
thrombocytopenic) patients. Nevertheless, this type of prophylaxis may increase the hemorrhagic 
risk and patients should be carefully monitored. Additional limiting aspects are the high cost of 
treatment, the lower patient compliance because of the need for self-injection and also the risk of 
renal impairment [Palumbo et al. 2011]. Indeed, most of LMWH is cleared via the renal route and 
LMWH therapy should be adjusted when the creatinine clearance is <30 ml/min to avoid drug 
accumulation and consequently an increase risk of bleeding. Kidney function is often altered in 
patients with multiple myeloma, thus a constant close monitoring is necessary when administering 
LMWH to these patients [Dimopoulos et al. 2008]. 
Aspirin 
ASA showed to reduce the risk of arterial complication [Cohen et al. 1994] but its role in venous 
thromboprophylaxis remains controversial. Although LMWH and warfarin-type prophylaxes are 
considered more efficient, there are data demonstrating that ASA reduces the risk of VTE in 
multiple myeloma patients treated with thalidomide [Hovens et al. 2006; Niesvizky et al. 2007]. 
One trial has reported a protective role of ASA in first-line therapy of patients with multiple 
myeloma treated with thalidomide and anthracyclines. The rate of thrombosis dramatically 
decreased (from 55% to 18%) when ASA was administered [Baz et al. 2005]. A significant risk 
reduction in both arterial and venous thrombosis with ASA was seen also in other similar studies 
[Pulmonary Embolism Prevention (PEP) Trial Collaborative Group, 2000]. 
Warfarin 
Warfarin is an oral anticoagulant commonly prescribed to treat VTE and to decrease the risk of 
VTE in AF [Ansell et al. 2008]. Warfarin therapy is complicated by the wide interindividual 
variation in response and dose requirements for adequate anticoagulation. Optimal warfarin therapy 
is achieved by maintaining the anticoagulation response, International Normalized Ratio (INR), 
within a narrow therapeutic range of 2.0–3.0 for most indications. In multiple myeloma, warfarin-
type drugs increase the incidence of hemorrhage when the INR is above 3. This bleeding risk is 
further increased in patients who become thrombocytopenic particularly with a platelet count below 
80 g/l. Owing to the unpredictable pharmacokinetic and pharmacodynamic responses to warfarin, 
initiation of therapy is the most clinically challenging phase as the optimal dose is often determined 
iteratively, guided by INR [Landefeld and Beyth, 1993]. Low-dose warfarin corresponds to a dose 
of 2.5–5 mg/day, while full dose warfarin corresponds to the dose adjusted according to INR (target 
2.0–3.0). Fixed low-dose warfarin corresponds to warfarin 1–1.25 mg/day. 
How to manage thromboembolic prophylaxis in patients receiving 
thalidomide-containing regimens 
Patients receiving thalidomide with chemotherapy or dexamethasone are at high risk for thrombosis 
and warrant prophylaxis [Lyman et al. 2007, 2007]. The choice of thromboprophylaxis should be 
based on the presence of individual and myeloma-related risk factors. Patients may be divided into 
two subcategories: standard and high-risk patients. If none of these risk factors is present, the 
patient is considered at standard risk. The simultaneous presence of more than one risk factor 
exponentially increases the risk of VTE [Palumbo et al. 2008b]. Myeloma-related risk factors such 
as the combination of thalidomide with high-dose dexamethasone or doxorubicin or multi-agent 
chemotherapy should be considered as high-risk factors (Table 1). 
In newly diagnosed myeloma patients treated with single-agent thalidomide, thromboprophylaxis is 
not usually recommended, while it is suggested when thalidomide is combined with other agents. 
The risk of VTE is much lower at relapse, so antithrombotic prophylaxis may be suggested only in 
high-risk patients in this setting. LMWH or full-dose warfarin should be administered in all patients 
who receive thalidomide with high-dose dexamethasone or doxorubicin or multi-agent 
chemotherapy. 
LMWH prophylaxis is widely used, while warfarin is scarcely used in the routine clinical practice 
because of the risk of hemorrhage in patients receiving active chemotherapy that could increase the 
risk of thrombocytopenia. The correct dose of LMWH to administer for thromboprophylaxis is 
defined according to the patients’ weight; monitoring of the anti-Xa level is not required except in 
the case of extremes of body weight (<50 kg, >100 kg), prosthetic heart valves or impaired renal 
function. 
A prophylactic anti-Xa level for LMWH is considered 0.1–0.3 IU/ml 4 hours after a dose of 
LMWH, in the case of prosthetic heart valves it is higher 0.8–1.2 IU/ml. 
In case of thromboprophylaxis using dalteparin, the dose to administer is 2500–5000 units daily, 
while enoxaparin is 40 mg once daily. 
Renal impairment may be a limit in the use of LMWH prophylaxis, due to the renal elimination of 
the drug, the consequent risk of accumulation and increased risk of bleeding. In this case, full-dose 
warfarin is recommended. 
In patients presenting with a standard risk to develop VTE or treated with thalidomide as single-
agent, anti-aggregation therapy with low-dose ASA should be considered. In the case of the 
presence of additional risk factors, which increase the risk of VTE, even in patients receiving 
thalidomide as a single agent, LWMH or full-dose warfarin are recommended (Table 1). 
Thromboprophylaxis should be continued for 3–6 months. Treatment with LMWH should be given 
for at least 6 months. Indefinite treatment should be considered for selected patients with active 
cancer, such as those with active disease and receiving chemotherapy. Anticoagulation should be 
avoided in the presence of intracranial bleeding, recent surgery, preexisting bleeding diathesis such 
as thrombocytopenia, platelet count <50,000/µl or coagulopathy. 
For myeloma patients, constant monitoring of platelet count during chemotherapy and 
antithrombotic prophylaxis is necessary. 
Rivaroxaban and dabigatran etexilate are the first new oral anticoagulants recently approved in the 
European Union, Canada and many other countries worldwide for the prevention of VTE in adult 
patients undergoing elective hip or knee replacement surgery [Friedman, 2009]. Fondaparinux is the 
first agent of a new class of selective factor Xa inhibitors (pentasaccharides). This drug was first 
approved for VTE prophylaxis in patients undergoing major orthopedic procedures and more 
recently was also approved to manage PE and DVT [Buller et al. 2003, 2004]. 
These newer and effective antithrombotic agents with reduced drug interactions and without the 
need for constant monitoring could optimize patient care and eventually modify the indication for 
use and duration of thromboprophylaxis, but further investigation is needed. 
Conclusion 
In conclusion, myeloma patients treated with thalidomide require routine thromboprophylaxis. 
ASA, LMWH and warfarin showed similar efficacy in reducing serious thromboembolic events, 
except in elderly patients where fixed low-dose warfarin showed less efficacy than LMWH. 
Although it could be an attractive option, fixed low-dose warfarin needs more extensive 
investigation. 
The specific thromboprophylaxis should be given according to individual risk factors and the type 
of therapy. It is crucial to identify patients at high risk of VTE in order to intervene promptly and to 
administer an appropriate prophylaxis, thus limiting the incidence of serious adverse events. 
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